Comparative Pharmacology
Head-to-head clinical analysis: CLINDAMYCIN PHOSPHATE IN 0 9 SODIUM CHLORIDE versus MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINDAMYCIN PHOSPHATE IN 0 9 SODIUM CHLORIDE versus MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER.
CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE vs MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, suppressing peptide bond formation. It has bacteriostatic activity against susceptible organisms.
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
600 mg to 900 mg IV every 8 hours, or 900 mg to 1200 mg IV every 12 hours. Maximum 4800 mg/day.
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
None Documented
None Documented
Terminal elimination half-life is 2-4 hours in adults, 2.5-3.5 hours in children, and prolonged to 4-6 hours in severe hepatic impairment; clinically relevant for dosing interval (typically q6-8h).
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
Approximately 10-20% renal excretion as active clindamycin and its metabolites; 40-60% biliary/fecal excretion as inactive metabolites; primarily hepatic metabolism with enterohepatic circulation.
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
Category A/B
Category C
Electrolyte
Electrolyte